Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ABBV - AbbVie Inc.


170.39
0.620   0.364%

Share volume: 51,025
Last Updated: Fri 24 Jan 2025 04:29:40 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%

$169.77
0.62
0.37%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
54%
Profitability 33%
Dept financing 32%
Liquidity 11%
Performance 92%
Company vs Stock growth
vs
Performance
5 Days
-1.12%
1 Month
-5.18%
3 Months
-10.01%
6 Months
-3.14%
1 Year
3.93%
2 Year
15.56%
Key data
Stock price
$170.39
P/E Ratio 
67.56
DAY RANGE
$169.32 - $170.72
EPS 
$2.88
52 WEEK RANGE
$153.58 - $207.32
52 WEEK CHANGE
$3.81
MARKET CAP 
346.054 B
YIELD 
3.13%
SHARES OUTSTANDING 
1.766 B
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
N/A
BETA 
0.28
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,083,124
AVERAGE 30 VOLUME 
$5,394,227
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

Recent news